. T is molecule has a globular head that faces outward and a stem domain that inserts into the viral lipid membrane and is the most conserved region of the HA protein. T e stem domain is the target for many naturally occurring human monoclonal antibodies (mAbs) that cross-react with multiple inf uenza strains from diverse subtypes and are of en encoded by a single antibody variable-gene segment designated V H 1-69. Single mAbs that mediate neutralization of inf uenza type A viruses of more than one antigenic subtype have been isolated, and indeed, some of these antibodies bind to representative HA molecules from all known inf uenza A subtypes.
T ese unexpected results have led innovative scientists to pursue the development of recombinant mimetics of the stem region of HA that could serve as the antigenic basis of a universal inf uenza vaccine. T e rationale behind these ef orts is that the highly variable HA head domain is immunodominant and diverts the human immune response away from the more conserved epitopes in the stem region, which could be more immunogenic if presented in a more immune system-accessible form. Of course, achieving a safe, immunogenic inf uenza vaccine that induces durable immunity to diverse virus subtypes would be one of the major accomplishments in the history of biomedicine, and the possibility that we may see this outcome during our professional lives is tantalizing.
FLU FEVER
In our zeal to plunge forward in the development and deployment of next-generation inf uenza vaccines, we should remain true to the core principles of vaccine development and testing, which include a strong focus on safety and minimization of risk. In this issue of Science Translational Medicine, Khurana et al.
(1) used a pig model of pandemic inf uenza H1N1 infection to investigate the ef ect of high-level induction of HA stem region-specif c antibodies in pigs that were vaccinated with a whole-inactivated H1N2 virus vaccine and subsequently challenged with the pandemic H1N1 virus, which is antigenically mismatched. In this experimental setting, the H1N2 vaccine induced antibodies that bound to an immunodominant epitope in the HA stem region that mediated enhanced H1N1 viral fusion to host cells and were associated with more frequent and more severe pneumonia in vaccinated animals. T is observation suggests that we need to better understand the molecular basis for neutralization of inf uenza viruses in polyclonal responses in vivo before assuming that immunogenic HA stem-region antigens will always be safe immunization targets simply because such vaccines are immunogens that do not grow in cells like live viruses do. I distinctly recall the sobriety of a moment early in my training in the 1990s, when asking several of the investigators in the Laboratory of Infectious Diseases at the U.S. National Institutes of Health what it was like to have directed the phase I trial of the ill-fated formalin-inactivated respiratory syncytial virus vaccine in the 1960s that was associated with the subsequent death of several children (8) . T e quiet wisdom that I received was to pay attention when experimental vaccinologists state, "this vaccine might not work, but we are sure it will be safe" before conducting clinical studies of new nonreplicating vaccines.
T e need to understand the molecular forces that drive antibody-enhanced virus replication or altered immune response is not limited to vaccine settings. In fact, it follows from the evidence presented by Khurana et al. that antibody-enhanced disease may occur in nature with an incidence that is hard to determine because of the high baseline morbidity caused by inf uenza infection itself. Studies during the 2009 H1N1 pandemic suggest that crossreactive human antibodies may have played a role in enhanced severe disease observed in otherwise healthy young adults, with similar f ndings also present in preserved lower-airway tissues from fatal cases during the 1957 H2 inf uenza pandemic (9) . T erefore, we should not interpret the new f ndings to indicate that inf uenza vaccines, in general, are of particular risk compared with natural infection. Current inf uenza vaccines do prevent a substantial amount of disease when the antigens are well matched. Nevertheless, inducing antibodies focused to the inf uenza HA stem region in the ab-FOCUS sence of antibodies to the head domain is a special strategy that deserves further study.
T e next steps in this f eld are to conduct experiments that help us to understand in detail the molecular basis for how antibodies neutralize or enhance inf uenza infection in vivo. Several mechanisms for enhanced disease are possible (Fig. 1) . T e studies of Khurana et al. in the pig model suggest that some stem-region-specif c antibodies alter the function of the HA protein so that it fuses more readily to susceptible cells; thus, the antibodies may facilitate higher levels of virus replication (Fig. 1A) . Another possible mechanism is that nonneutralizing antibodies might bind the virus and direct it to Fc receptor-bearing cells that become infected through Fc receptor-mediated endocytosis (Fig. 1B) . T is mechanism is commonly studied in dengue virus models, but it is not clear whether inf uenza A virus replicates ef ciently in Fc receptor-bearing cells, such as professional antigen-presenting cells. Further, antibodies might enhance disease without altering virus replication. For example, viral antibodies can bind to virusinfected cells, spur deposition of complement proteins, and cause antibody-mediated complement activation, which leads to direct tissue damage (Fig. 1C) .
T e promise of universal inf uenza vaccines has excited biomedical scientists around the globe. Work in this f eld should proceed and will. T e imperative now is to def ne the mechanisms of antibodymediated neutralization and enhancement and to understand the complex balance of these forces that occur in polyclonal antibody responses in vivo. T e recent explosion of reductionist studies of the structural and chemical basis of the action of inf uenza mAbs is helpful, but we also need methods for tweezing apart the polyclonal responses of B cell populations in the context of viral infections in vivo. T e mAbs directed to inf uenza HA protein epitopes that have been studied to date merely represent members of large antibody "swarms" of related somatic variant antibodies that occur in human responses (10) . Understanding the balance of forces within diverse populations of antibodies will be challenging, but newly emerging techniques will allow us to tackle these problems. High-throughput sequence analysis of the gene segments that encode antibody repertoires, proteomic studies of the protein sequences of secreted antibodies, and other evolving techniques will provide the high-information-content tools we need to develop, test, and use next-generation inf uenza vaccines that provide protection without harm. 
